Payment overview · 2025
General Payments
$1,428.90
78 reported records · 21 companies
Healthcare provider profile · identity verified
Benjamin Panglao Marquez, MD
Allopathic & Osteopathic Physicians|Family Medicine · SUN CITY CENTER, FL · NPI 1235147182
Verified facts
What the public records show
CMS Open Payments records show Benjamin Panglao Marquez, MD received $1,428.90 in general payments during 2025 across 78 reported records.
Amgen Inc. accounted for 14.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 261 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulance by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $201.21 | 14.1% | 17 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $163.88 | 11.5% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $153.16 | 10.7% | 9 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $88.83 | 6.2% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $85.90 | 6.0% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $80.37 | 5.6% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $79.56 | 5.6% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $73.56 | 5.2% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $73.56 | 5.2% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $66.27 | 4.6% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $61.49 | 4.3% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $55.71 | 3.9% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $40.37 | 2.8% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $39.40 | 2.8% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $39.37 | 2.8% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $31.43 | 2.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.31 | 1.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.08 | 1.6% | 1 | 2025 |
| BIOTRONIK NRO, Inc. | Unresolved — no canonical attribution shown | $20.05 | 1.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $14.45 | 1.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.94 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,428.90 | 78 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $111.47 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $111.47 | 9 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $100.35 | 5 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $89.74 | 8 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $88.83 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $85.92 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $84.02 | 5 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $80.37 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $79.56 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $76.52 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $73.56 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $66.27 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $61.49 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $55.71 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $55.28 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $52.03 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $40.37 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $39.40 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $39.37 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $35.72 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $32.11 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $32.11 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $31.43 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $25.23 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $25.23 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $25.23 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.31 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.08 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $20.07 | 1 | 2025 |
Source payment records
|
|||||
| Prospera Normalized: prospera |
Device | BIOTRONIK NRO, Inc. | $20.05 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $16.22 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $13.94 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 38 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 55 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 52 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 58 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 58 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 35 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
148 | 41 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
52 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
38 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
52 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
35 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
52 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
58 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
58 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
261 | 55 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
55 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1158 | 342 |
| Levothyroxine Sodium | Levothyroxine Sodium | 904 | 256 |
| Amlodipine Besylate | Amlodipine Besylate | 673 | 208 |
| Losartan Potassium | Losartan Potassium | 507 | 157 |
| Furosemide | Furosemide | 466 | 154 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 390 | 124 |
| Pantoprazole Sodium | Pantoprazole Sodium | 375 | 124 |
| Metformin Hcl | Metformin Hcl | 359 | 105 |
| Lisinopril | Lisinopril | 347 | 115 |
| Alprazolam | Alprazolam | 325 | 96 |
| Gabapentin | Gabapentin | 309 | 113 |
| Tamsulosin Hcl | Tamsulosin Hcl | 275 | 92 |
| Metoprolol Succinate | Metoprolol Succinate | 268 | 93 |
| Potassium Chloride | Potassium Chloride | 268 | 79 |
| Eliquis | Apixaban | 261 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 229 | 69 |
| Omeprazole | Omeprazole | 228 | 80 |
| Meloxicam | Meloxicam | 225 | 73 |
| Metoprolol Tartrate | Metoprolol Tartrate | 222 | 66 |
| Simvastatin | Simvastatin | 213 | 70 |
| Trazodone Hcl | Trazodone Hcl | 203 | 65 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 185 | 36 |
| Prednisone | Prednisone | 183 | 98 |
| Donepezil Hcl | Donepezil Hcl | 178 | 44 |
| Glipizide Er | Glipizide | 165 | 48 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 165 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 161 | 52 |
| Pravastatin Sodium | Pravastatin Sodium | 156 | 50 |
| Sertraline Hcl | Sertraline Hcl | 149 | 49 |
| Synthroid | Levothyroxine Sodium | 148 | 41 |
| Allopurinol | Allopurinol | 142 | 40 |
| Memantine Hcl | Memantine Hcl | 140 | 30 |
| Montelukast Sodium | Montelukast Sodium | 134 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 128 | 41 |
| Tramadol Hcl | Tramadol Hcl | 127 | 41 |
| Finasteride | Finasteride | 113 | 34 |
| Alendronate Sodium | Alendronate Sodium | 106 | 36 |
| Azithromycin | Azithromycin | 106 | 95 |
| Famotidine | Famotidine | 105 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 100 | 37 |
| Methylprednisolone | Methylprednisolone | 100 | 85 |
| Pioglitazone Hcl | Pioglitazone Hcl | 100 | 33 |
| Lovastatin | Lovastatin | 97 | 28 |
| Atenolol | Atenolol | 95 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 94 | 25 |
| Ezetimibe | Ezetimibe | 93 | 30 |
| Carvedilol | Carvedilol | 92 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 91 | 44 |
| Hydralazine Hcl | Hydralazine Hcl | 90 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 88 | 29 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 87 | 24 |
| Januvia | Sitagliptin Phosphate | 85 | 23 |
| Celecoxib | Celecoxib | 76 | 31 |
| Ibuprofen | Ibuprofen | 74 | 26 |
| Glipizide | Glipizide | 69 | 19 |
| Metformin Hcl Er | Metformin Hcl | 69 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 68 | 33 |
| Ipratropium Bromide | Ipratropium Bromide | 66 | 23 |
| Xarelto | Rivaroxaban | 66 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 65 | 19 |
| Benazepril Hcl | Benazepril Hcl | 64 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 61 | 24 |
| Meclizine Hcl | Meclizine Hcl | 60 | 32 |
| Mounjaro | Tirzepatide | 58 | 16 |
| Ozempic | Semaglutide | 58 | 21 |
| Fenofibrate | Fenofibrate | 55 | 20 |
| Gemtesa | Vibegron | 55 | 14 |
| Spironolactone | Spironolactone | 55 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 54 | 15 |
| Midodrine Hcl | Midodrine Hcl | 54 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | 15 |
| Jardiance | Empagliflozin | 52 | 16 |
| Myrbetriq | Mirabegron | 52 | 16 |
| Diazepam | Diazepam | 50 | 15 |
| Nifedipine Er | Nifedipine | 49 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 48 | 44 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 47 | 14 |
| Glimepiride | Glimepiride | 46 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 46 | 18 |
| Baclofen | Baclofen | 45 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 45 | 19 |
| Pregabalin | Pregabalin | 45 | 17 |
| Lorazepam | Lorazepam | 44 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 44 | 12 |
| Buspirone Hcl | Buspirone Hcl | 43 | 12 |
| Valsartan | Valsartan | 41 | suppressed |
| Clonazepam | Clonazepam | 38 | 13 |
| Farxiga | Dapagliflozin Propanediol | 38 | 16 |
| Topiramate | Topiramate | 38 | suppressed |
| Cephalexin | Cephalexin | 37 | 30 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 37 | 13 |
| Lactulose | Lactulose | 36 | 13 |
| Mirtazapine | Mirtazapine | 36 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 35 | suppressed |
| Aripiprazole | Aripiprazole | 35 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 35 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 34 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 27 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 32 | 12 |
| Primidone | Primidone | 32 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | 13 |
| Solifenacin Succinate | Solifenacin Succinate | 32 | 13 |
| Methenamine Hippurate | Methenamine Hippurate | 31 | suppressed |
| Verapamil Er | Verapamil Hcl | 31 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 31 | suppressed |
| Bupropion Xl | Bupropion Hcl | 30 | suppressed |
| Nystatin | Nystatin | 30 | 11 |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Trulicity | Dulaglutide | 30 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 29 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 29 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 24 |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | 11 |
| Mupirocin | Mupirocin | 28 | 22 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 11 |
| Ranolazine Er | Ranolazine | 27 | suppressed |
| Bumetanide | Bumetanide | 26 | suppressed |
| Clotrimazole | Clotrimazole | 26 | 11 |
| Nitroglycerin | Nitroglycerin | 26 | 11 |
| Sildenafil Citrate | Sildenafil Citrate | 26 | suppressed |
| Sucralfate | Sucralfate | 26 | 14 |
| Telmisartan | Telmisartan | 26 | suppressed |
| Temazepam | Temazepam | 26 | 11 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 26 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 25 | 14 |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Acyclovir | Acyclovir | 24 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | 18 |
| Morphine Sulfate Er | Morphine Sulfate | 24 | suppressed |
| Movantik | Naloxegol Oxalate | 24 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 18 |
| Estradiol | Estradiol | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Invokana | Canagliflozin | 20 | suppressed |
| Latanoprost | Latanoprost | 20 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Modafinil | Modafinil | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 13 |
| Trulance | Plecanatide | 17 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | 11 |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Sulfasalazine | Sulfasalazine | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Klor-Con 10 | Potassium Chloride | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 12 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 12 | suppressed |
| Avonex Pen (4 Pack) | Interferon Beta-1a | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Cholestyramine Light | Cholestyramine | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Lumigan | Bimatoprost | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,428.90 · 78 records | Amgen Inc. | ABRYSVO, AIRSUPRA, AUSTEDO XR, BREZTRI, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, GEMTESA, JARDIANCE, Kerendia, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, Prospera, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error